Could a safer drug replace standard antiviral for kidney transplant patients?
NCT ID NCT07294547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if valacyclovir works as well as valganciclovir to prevent CMV and EBV infections in kidney transplant patients. Valganciclovir can cause bone marrow suppression, a serious side effect. The study will enroll 80 kidney transplant recipients and monitor them for new infections and side effects over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIVIRAL PROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cells engineered to hunt viruses show promise for transplant kids
- Supercharged immune cells take on Drug-Resistant infections
- Donor cells take on Drug-Resistant viruses in new trial
- New antibody shows promise against Post-Transplant virus threat
- Virus tracking in kidney transplants may spot hidden risks
- Scientists seek tissue samples to unlock HIV and cancer mysteries